N/A
Completed N=415
Bridging Pediatric and Adult Biomarkers in Graft-Versus-Host Disease
Source: ClinicalTrials.gov NCT02194439 ↗Enrolled (actual)
415
Serious AEs
0.0%
Results posted
Feb 2021
Primary outcomePrimary: Number of Participants With Non Relapse Mortality (NRM) by Age and ST2 at 12 Months Post-HCT — 55; 115; 125; 120 participants
Summary
This study is designed to collect longitudinal biological samples from patients after hematopoietic cell transplantation (HCT) cared for at multiple bone marrow transplant centers to validate biomarkers of both acute and chronic GVHD as well as for use in future unspecified research. The centers include Dana-Farber Cancer Institute and Boston's Children's Hospital, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Fred Hutchinson Cancer Research Center, Texas Children's Hospital, Children's National Medical Center, and Indiana University Simon Cancer Center.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Non Relapse Mortality (NRM) by Age and ST2 at 12 Months Post-HCT |
55; 115; 125; 120 | — |
Eligibility Criteria
Inclusion Criteria: - All patients receiving an allogeneic hematopoietic stem cell transplant, cord blood transplant, bone marrow transplant, T cell depleted marrow, donor lymphocyte infusion (DLI), or donor cellular infusion (DCI) can be included.
Exclusion Criteria: - patients not receiving an allogeneic hematopoietic stem cell transplant, cord blood transplant, bone marrow transplant, T cell depleted marrow, donor lymphocyte infusion (DLI), or donor cellular infusion (DCI) will be excluded.
Data sourced from ClinicalTrials.gov (NCT02194439). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.